HER2 À½¼º À¯¹æ¾Ï(Breast Cancer)ȯÀÚ¿¡°Ô º¸Á¶ÀûÀÎ Capecitabine ÈÇпä¹ý Ä¡·áÈ¿°ú
¡à ÀÓ»óÁú¹®
Q. Anthracycline ȤÀº TaxaneÀÌ Æ÷ÇÔµÈ ½Åº¸Á¶Ç×¾ÏÈÇпä¹ý(ȤÀº µÑ ´Ù Æ÷ÇÔµÈ Ä¡·á)ÈÄ¿¡ Ç¥Áؼö¼ú ÈÄ Ä¡·á(standard postsurgical treatment)¸¦ ¹Þ±â À§ÇØ Ä«Æä½ÃŸºó(capecitabione)º¸Á¶¿ä¹ýÀÌ HERS À½¼ºÀ¯¹æ¾ÏȯÀÚÄ¡·á¿¡ È¿°úÀûÀԴϱî?
|
¡à ±Ù°Å±â¹Ý ´äº¯
A. CapecitabineÀº Ç¥ÁØ neoadjuvant ÈÇÐ ¿ä¹ý ÈÄ ÀÜ¿©Ä§½À¼ºÁúȯÀ» ¾Î°í ÀÖ´Â HER2 À½¼º À¯¹æ¾Ï ȯÀÚ¿¡¼ º¸Á¶Ä¡·áÀÇ È¿°ú¸¦ ³ªÅ¸ ³»¾ú¸ç, º¸Á¶Àû capecitabine Åõ¿©´ÂHER2 À½¼º À¯¹æ¾Ï ȯÀÚÀÇ Áúº´¾ø´Â »ýÁ¸·ü(Disease-free survival) ¹× Àüü»ýÁ¸À²(Overall Survival)±â°£À» ¿¬Àå½ÃÅ°´Âµ¥ ¾ÈÀüÇÏ°í È¿°úÀûÀ̾úÀ½À» º¸°íÇÏ¿´½À´Ï´Ù.
|
¡à ¼ÁöÁ¤º¸
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy (2017), The New England journal of medicine; 376( 22), 2147-2159
- DOI: 10.1056/NEJMoa1612645
Áúº´Æ¯¼º
|
½Åº¸Á¶ÈÇпä¹ý ÈÄ ¼ö¼úÀ» ¹ÞÀº HER2-negative Stage I-III À¯¹æ¾Ï
|
¿¬±¸¼³°è
|
- ¹«ÀÛÀ§½ÃÇè´ëÁ¶±º(Randomized contorlled trials) ¿¬±¸
- ÀϺ»°ú Çѱ¹ÀÇ 84°³±â°ü¿¡¼ 5³âµ¿¾È ¼öÇàÇÔ
|
¿¬±¸´ë»ó
|
Stage I-III À¯¹æ¾Ï (³ªÀÌ 20~74¼¼) ȯÀÚ 910¸í À» ´ë»óÀ¸·Î ÇÔ
|
½ÃÇ豺 ÁßÀç
|
Capecitabine 1250mg/m2 ÇÏ·ç¿¡ µÎ¹ø Åõ¿©ÇÑ ±×·ì 455¸í
|
´ëÁ¶±º ÁßÀç
|
CapecitabineÅõ¿© ¾øÀÌ Ç¥ÁØÄ¡·á(Standard therapy) ±×·ì 455¸í
|
Æò°¡ÁöÇ¥
|
Disease-free survival
Overall survival
|
ÁÖ¿ä°á°ú
|
º¸Á¶Àû capecitabine Åõ¿©´Â º´¸®Çа˻翡¼ ÀÜ¿© ħ½À¼º ÁúȯÀÌ ÀÖ´Â HER2 À½¼º À¯¹æ¾Ï ȯÀÚÀÇ Áúº´¾ø´Â »ýÁ¸·ü(Disease-free survival) ¹× Àüü»ýÁ¸À²(Overall Survival)±â°£À» ¿¬Àå½ÃÅ°´Âµ¥ È¿°úÀûÀ̾úÀ½À» º¸°íÇÏ¿´À½.
- The rate of disease-free survival: 69.8% in the capecitabine group versus 56.1% in the control group (hazard ratio for recurrence, second cancer, or death, 0.58; 95% CI, 0.39 to 0.87)
- The overall survival rate: 78.8% versus 70.3% (hazard ratio for death, 0.52; 95% CI, 0.30 to 0.90)
|
±Ù°Å¼öÁØ
|
Moderate
|
ÀÛ¼ºÀÚ : ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC) Copyright © 2015 Medical Research Information Center (MedRIC) Editors